Letter of Medical Necessity (Genetic Testing)

Date: [Date]

To: [Health plan name], [UM / Prior Authorization / Appeals Department], [Fax number or portal reference]

Re: [Patient full name], DOB: [Date of birth], Member ID: [Member ID], Group ID: [Group ID], Request type: [Prior Authorization / Appeal / Peer-to-Peer Request], Reference #: [PA or denial number], Requested test: [Test name] at [Performing laboratory]

From: [Ordering clinician name], [Credentials], [Specialty], NPI: [NPI], Practice: [Practice name and address], Direct contact: [Phone or email for peer-to-peer]

(Include if appeal:) Appeal context: Denial date: [Date]; Denial reason: [Reason in payer's words]; Response deadline: [Date]

(Include if time-sensitive:) Time-criticality: [Pregnancy / ICU / rapidly progressive disease / surgical decision] necessitates expedited review by [Date] because [Brief reason].

Opening Request

[One paragraph explicitly requesting coverage for the specific test, naming the suspected diagnosis or diagnostic category, stating why testing is needed now, and summarizing the core medical-necessity claim—that results will inform treatment, surveillance, and/or reproductive planning. Do not include detailed clinical history here.]

Test Requested

• Test name: [Test name as marketed]
• Test type: [Panel / Exome sequencing (ES) / Genome sequencing (GS) / Targeted single-gene] (ES sequences protein-coding regions; GS sequences nearly all DNA including non-coding regions; panels analyze selected genes for a specific condition.)
• Testing configuration: [Trio / Duo / Proband-only] (Trio includes patient plus both biological parents.)
• Performing laboratory: [Laboratory name]
• Specimen type: [Blood / Saliva / Buccal swab / Tissue]
• Scope: [High-level gene or condition scope without full gene list]
• Add-ons: [CNV analysis / Mitochondrial DNA sequencing / Repeat expansion testing / RNA analysis] (Include only if applicable.)
• Turnaround time: [Estimated weeks]
• CPT/HCPCS codes: [Codes if known]
• ICD-10-CM codes: [Primary and secondary diagnosis codes]
• (Include if payer requires step-testing justification:) Step-testing rationale: [Reason narrower test is insufficient, or documentation of prior negative step-tests with dates]

Clinical Indication Summary

(Lead with features supporting genetic etiology: multiple congenital anomalies, early onset, multisystem involvement, unexplained DD/ID, or strong family history. Include only pertinent negatives that materially narrow the differential.)

• Patient: [Age], [Sex]
• Key clinical features: [Primary symptoms and functional impact]
• Onset and course: [Age at onset], [Progression or stability], [Acute / episodic / chronic]
• Exam findings: [Pertinent objective findings and specialist assessments]
• Abnormal studies: [Key imaging, labs, EEG, EKG, echo, biopsy with dates and salient abnormalities]
• Working diagnosis: [Current clinical impression and top differential considerations]

Family History

(Include when relevant: suspected inherited disorder, multiple affected relatives, consanguinity, reproductive planning as justification, or testing strategy depends on inheritance pattern. Omit if not relevant and not required by payer.)

• Affected relatives: [Relationship, age of onset, key features or diagnoses]
• Known familial variants: [Gene and variant if known, source report]
• Ancestry: [Relevant ancestry if it affects pre-test probability]
• Consanguinity: [Present / Absent / Unknown]
• Pregnancy losses or neonatal deaths: [Details if pertinent]
• (If family history unavailable, state why: adoption, limited contact, unknown paternity, donor gametes.)

Prior Evaluation and Testing

(If early comprehensive testing is appropriate—critically ill infant, high suspicion, or guideline-supported first/second-tier ES/GS—state that explicitly rather than documenting extensive prior workup.)

• Test/Study: [Name] | Date: [Date] | Result: [Findings] | Implication: [How this influenced care or residual uncertainty]
• Test/Study: [Name] | Date: [Date] | Result: [Findings] | Implication: [Clinical implication]
• (Include prior genetic tests: CMA, Fragile X, single-gene, panels, mtDNA; relevant non-genetic evaluations: metabolic screening, imaging, biopsies; specialist evaluations.)
• Summary: [Statement that requested testing follows appropriate initial evaluation, or justification for early comprehensive testing]

Rationale for This Test

• Genetic etiology is likely because: [Objective features supporting genetic cause; non-genetic causes excluded or less likely]
• This test is most appropriate because: [Genetic heterogeneity / phenotype overlaps many disorders / prior tests negative or incomplete, so panel/ES/GS has best diagnostic yield]
• Alternatives are insufficient because: [Single-gene testing is low yield / sequential panels increase cost and delay / phenotype does not point to one gene]
• Trio testing: [Is / Is not] planned because [Parental data aids variant interpretation and inheritance confirmation]
• Secondary findings: [Will / Will not] be analyzed per patient preference; opt-out [offered / declined]. (Secondary findings are results unrelated to the primary indication but with potential health impact.)

How Results Will Change Management

(Use conditional language: "would prompt," "may guide." List specific, plausible actions tied to the clinical scenario.)

If Positive (pathogenic or likely pathogenic variant):

• [Treatment changes: initiation or avoidance of specific medications, diets, or therapies]
• [Surveillance protocols: imaging, cardiac, neurologic, or other screening at defined intervals]
• [Specialist referrals or multidisciplinary clinic enrollment]
• [Avoidance of harmful or futile procedures or tests]
• [Prognosis and anticipatory guidance for care planning]
• [Cascade testing for at-risk relatives] (testing offered to family members to clarify their risk)
• [Recurrence risk counseling and reproductive options: carrier testing, prenatal diagnosis, PGT]

If Negative (no diagnostic findings):

• [Refine differential diagnosis and redirect evaluation]
• [Avoid repeated low-yield testing and unnecessary procedures]
• [Consider alternative modalities: genome sequencing, RNA analysis, functional studies]

If Uncertain (VUS or partial findings):

• [Segregation testing in relatives to determine if variant tracks with disease]
• [Periodic reanalysis of genomic data as knowledge evolves]
• [Correlation with evolving clinical features]

(VUS: a variant of uncertain significance where current evidence is insufficient to determine pathogenicity.)

Guideline Support

(Include when payer cites policy criteria in denial, for ES/GS requests, or when published guidelines support the indication. Keep to 2–5 bullets.)

• [Guideline name] supports [test type] when [criteria]. Patient meets criteria because [brief mapping to features].
• [Specialty society guidance] recommends [test] under [criteria], which apply due to [patient features].
• [Payer policy language] aligns with [guideline], met by [documented findings].

Counseling and Consent

(Include for ES/GS or large panels.)

• Pre-test genetic counseling [completed / scheduled] with [Genetic counselor / Clinician], covering potential result types and test limitations.
• Secondary findings discussion with [opt-in / opt-out] documented per patient preference.
• Consent [obtained / will be obtained] per laboratory and institutional policy.

Closing Request

[One paragraph restating the requested test, indication, and key management impact. Request specific action: authorization, overturn of denial, expedited review, or peer-to-peer scheduling. Provide direct contact information and availability.]

Enclosures

• [Clinic notes supporting the indication]
• [Prior genetic test reports]
• [Key imaging and laboratory reports]
• [Pedigree or family history summary]
• [Denial letter and policy citation] (for appeals)

Signature

[Ordering clinician name], [Credentials], NPI: [NPI]

[Signature]

(If drafted by genetic counselor:) Prepared by: [Genetic counselor name], [Credentials]. [Supervising clinician co-signature if required by payer.]